

LISTING OF CLAIMS

Please cancel claims 3, 21, 40, 85 and 95 without prejudice to subsequent renewal or future prosecution. Please amend the other pending claims as follows. The following listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1. (previously presented) An isolated mammalian anti-Dengue virus antibody, comprising at least one variable region comprising the amino acid sequence set forth in SEQ ID NO: 4.

Claim 2. (original) An antibody according to Claim 1, wherein said antibody binds Dengue virus NS-1 protein.

Claim 3. (**Canceled**)

Claim 9. (**Currently amended**) A composition comprising at least one isolated mammalian anti-Dengue virus antibody having at least one variable region comprising ~~an~~the amino acid sequence set forth in SEQ ID NO: 4, and at least one pharmaceutically acceptable carrier or diluent.

Claim 11. (withdrawn) A method for diagnosing or treating a Dengue virus-related condition in a cell, tissue, organ, patient or animal, comprising:

(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody of claim 1, with, or to, said cell, tissue, organ, patient or animal.

Claim 12. (withdrawn) A method according to Claim 11, wherein said effective amount is 0.001 to 50 mg/kilogram of said

cells, tissue, organ, patient or animal.

Claim 13. (withdrawn) A method according to Claim 11, wherein said contacting or said administering is by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 14. (withdrawn) A method according to Claim 11, further comprising administering, prior, concurrently or after said (a) contacting or administering, at least one composition comprising an effective amount of at least one compound or protein selected from the group consisting of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

Claim 15. (previously presented) A medical device, comprising at least one isolated mammalian anti-Dengue virus antibody having at least one variable region comprising SEQ IN

NO: 4, wherein said device is suitable to contacting or administering said at least one anti-Dengue virus antibody by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 16. (previously presented) An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of at least one isolated mammalian anti-Dengue virus antibody having at least one variable region comprising SEQ ID NO: 4.

Claim 17. (previously presented) The article of manufacture of Claim 16, wherein said container is a component of a delivery device or system using a mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal,

intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 19. (**Currently amended**) An isolated mammalian anti-Dengue virus antibody having at least one variable region comprising SEQ ID NO: 4 produced by a method comprising providing a host cell or a non-human transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said antibody.

Claim 20. **Currently amended**) An isolated mammalian anti-Dengue virus antibody, comprising all of the light chain CDR ~~amino acids~~ sequences of SEQ ID NO: 4.

Claim 21. (**Canceled**)

Claim 22. (original) A Dengue virus antibody according to Claim 20, wherein said antibody binds at least one Dengue virus NS 1 protein.

Claim 28. (**Currently amended**) A composition comprising at least one isolated mammalian anti-Dengue virus antibody having all of the light chain CDR ~~amino acids~~ sequences of SEQ ID NO: 4, and at least one pharmaceutically acceptable carrier or diluent.

Claim 29. (previously presented) A composition according to Claim 28, further comprising at least one composition comprising a therapeutically or prophylactically effective amount of at least one compound or protein selected from the group consisting of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an

antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

Claim 30. (withdrawn) A method for diagnosing or treating a Dengue virus-related condition in a cell, tissue, organ, patient, animal or population of subjects comprising:

(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody of claim 20, with, or to, said cell, tissue, organ, patient or animal.

Claim 31. (withdrawn) A method according to Claim 30, wherein said effective amount is 0.001 to 50 mg/kilogram of said cells, tissue, organ, patient or animal.

Claim 32. (withdrawn) A method according to Claim 30, wherein said contacting or said administering is by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 33. (withdrawn) A method according to Claim 30, further comprising administering, prior, concurrently or after said (a) contacting or administering, at least one composition comprising a therapeutically or prophylactically effective amount of at least one compound or protein selected from the group consisting of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

Claim 34. (**Currently amended**) A medical device, comprising at least one isolated mammalian anti-Dengue virus antibody having all of the light chain CDR ~~amino acids~~ sequences of SEQ ID NO: 4, wherein said device is suitable to contacting or administering said at least one anti-Dengue virus antibody by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelical, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 35. (**Currently amended**) An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of at least one isolated mammalian anti-Dengue virus antibody having all of the light chain CDR ~~amino acids~~ sequences of SEQ ID NO: 4.

Claim 36. (previously presented) The article of manufacture of Claim 35, wherein said container is a component of a delivery device or system which uses a mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 38. (**Currently amended**) An isolated mammalian anti-Dengue virus antibody having all of the light chain CDR ~~amino acid~~ sequences of SEQ ID NO: 4 produced by a method comprising providing a host cell or a non-human transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts nucleic acid molecules encoding said antibody.

Claim 39. (**Currently amended**) An isolated mammalian anti-Dengue virus antibody, comprising at least one light chain CDR ~~having the amino acid sequence of~~ shown in SEQ ID NO: 4.

Claim 40. (**Canceled**)

Claim 41. (Original) A Dengue virus antibody according to Claim 39, wherein said antibody binds at least one Dengue virus NS 1 protein.

Claim 47. (**Currently amended**) A composition comprising at least one isolated mammalian anti-Dengue virus antibody having at least one light chain CDR ~~having the amino acid sequence of at least one of shown in~~ SEQ ID NO: 4, and at least one pharmaceutically acceptable carrier or diluent.

Claim 49. (withdrawn) A method for diagnosing or treating a Dengue virus related condition in a cell, tissue, organ, patient or animal, comprising:

(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody of claim 1, with, or to, said cell, tissue, organ, patient or animal.

Claim 50. (withdrawn) A method according to Claim 49, wherein said effective amount is 0.001 to 50 mg/kilogram of said cells, tissue, organ, patient or animal.

Claim 51. (withdrawn) A method according to Claim 49, wherein said contacting or said administering is by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic,

intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 52. (withdrawn) A method according to Claim 49, further comprising administering, prior, concurrently or after said (a) contacting or administering, at least one composition comprising an effective amount of at least one compound or protein selected from the group consisting of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

Claim 53. (**Currently amended**) A medical device, comprising at least one isolated mammalian anti-Dengue virus antibody having at least one light chain CDR ~~having the amino acid sequence of~~ shown in SEQ ID NO: 4, wherein said device is suitable to contacting or administering said at least one anti-Dengue virus antibody by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelical, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine,

intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 54. (**Currently amended**) An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising at least one isolated mammalian anti-Dengue virus antibody ~~or nucleic acid molecule encoding said antibody,~~ having at least one light chain CDR ~~having the amino acid sequence of shown in~~ SEQ ID NO: 4.

Claim 55. (previously presented) The article of manufacture of Claim 54, wherein said container is a component of a delivery device or system that uses a mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 57. (**Currently amended**) An isolated mammalian anti-Dengue virus antibody having at least one light chain CDR ~~having the amino acid sequence of shown in~~ SEQ ID NO: 4 produced by a method comprising providing a host cell or a non-human transgenic animal or transgenic plant or plant cell capable of expressing a nucleic acid molecule encoding said antibody in recoverable amounts wherein said nucleic acid molecule comprises SEQ ID NO: 2.

Claim 58. (**Currently amended**) An isolated mammalian anti-Dengue virus monoclonal antibody that binds to the same region of a Dengue virus protein as an monoclonal antibody comprising at least one light chain CDR ~~having the amino acid sequence of shown~~ in SEQ ID NO: 4.

Claim 59. (**currently amended**) A Dengue virus monoclonal antibody according to Claim 58, wherein said antibody binds a Dengue virus NS-1 protein.

Claim 60. (**currently amended**) A Dengue virus monoclonal antibody according to Claim 58, wherein said antibody substantially neutralizes at least one activity of at least one Dengue virus NS-1 protein.

Claim 66. (**Currently amended**) A composition comprising at least one isolated mammalian anti-Dengue virus monoclonal antibody that binds to the same region of a Dengue virus protein as an monoclonal antibody comprising at least one light chain CDR ~~having the amino acid sequence of shown in~~ in SEQ ID NO: 4, and at least one pharmaceutically acceptable carrier or diluent.

Claim 68. (withdrawn) A method for diagnosing or treating a Dengue virus related condition in a cell, tissue, organ, patient or animal, comprising:

(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody that binds to the same region of a Dengue virus protein as the antibody of claim 1, with, or to, said cell, tissue, organ, patient or animal.

Claim 69. (withdrawn) A method according to Claim 68, wherein said effective amount is 0.001 to 50 mg/kilogram of said

cells, tissue, organ, patient or animal.

Claim 70. (withdrawn) A method according to Claim 68, wherein said contacting or said administering is by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelical, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 71. (withdrawn) A method according to Claim 68, further comprising administering, prior, concurrently or after said step (a) contacting or administering, at least one composition comprising an effective amount of at least one compound or protein selected from the group consisting of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

Claim 72. (**Currently amended**) A medical device, comprising at least one isolated mammalian anti-Dengue virus monoclonal

antibody ~~or nucleic acid molecule encoding said antibody~~ that binds to the same region of a Dengue virus protein as an monoclonal antibody comprising at least one light chain CDR ~~having the amino acid sequence of shown in~~ SEQ ID NO: 4, wherein said device is suitable to contacting or administering said at least one anti-Dengue virus antibody by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 73. (**Currently amended**) An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising at least one isolated mammalian anti-Dengue virus monoclonal antibody ~~or nucleic acid molecule encoding said antibody~~ that binds to the same region of a Dengue virus protein as an monoclonal antibody comprising at least one light chain CDR ~~having the amino acid sequence of shown in~~ SEQ ID NO: 4.

Claim 74. (previously presented) The article of manufacture of Claim 73, wherein said container is a component of a delivery device or system which uses a mode of delivery selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial,

intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 76. **Currently amended**) An isolated population of monoclonal mammalian anti-Dengue virus monoclonal antibody that binds to the same region of a Dengue virus protein as an monoclonal antibody comprising at least one light chain CDR ~~having the amino acid sequence of shown in~~ SEQ ID NO: 4 produced by a method comprising providing a host cell or a non-human transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said antibody.

Claim 85. (**Canceled**)

Claim 95. (**Canceled**)